Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 4
2017 1
2018 5
2019 2
2020 2
2021 2
2022 6
2023 5
2024 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
PARP Inhibitors Resistance: Mechanisms and Perspectives.
Giudice E, Gentile M, Salutari V, Ricci C, Musacchio L, Carbone MV, Ghizzoni V, Camarda F, Tronconi F, Nero C, Ciccarone F, Scambia G, Lorusso D. Giudice E, et al. Among authors: ghizzoni v. Cancers (Basel). 2022 Mar 10;14(6):1420. doi: 10.3390/cancers14061420. Cancers (Basel). 2022. PMID: 35326571 Free PMC article. Review.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
New medical approaches in advanced ovarian cancer.
Corrado G, Palluzzi E, Bottoni C, Pietragalla A, Salutari V, Ghizzoni V, Distefano M, Scambia G, Ferrandina G. Corrado G, et al. Among authors: ghizzoni v. Minerva Med. 2019 Aug;110(4):367-384. doi: 10.23736/S0026-4806.19.06139-1. Epub 2019 May 22. Minerva Med. 2019. PMID: 31124637 Review.
Recent progress in the use of pharmacotherapy for endometrial cancer.
Giudice E, Salutari V, Ricci C, Nero C, Carbone MV, Musacchio L, Ghizzoni V, Perri MT, Camarda F, Tronconi F, Lorusso D, Scambia G. Giudice E, et al. Among authors: ghizzoni v. Expert Opin Pharmacother. 2023 Jan;24(1):83-94. doi: 10.1080/14656566.2022.2106782. Epub 2022 Aug 5. Expert Opin Pharmacother. 2023. PMID: 35912837 Review.
Management of early-stage ovarian cancer: Open questions and debated issues.
Salutari V, Giudice E, Rapisarda E, Pavone M, Ghizzoni V, Perri MT, Boccia SM, Lardino S, Gallotta V, Fagotti A, Scambia G, Lorusso D. Salutari V, et al. Among authors: ghizzoni v. Crit Rev Oncol Hematol. 2025 Jun;210:104704. doi: 10.1016/j.critrevonc.2025.104704. Epub 2025 Mar 17. Crit Rev Oncol Hematol. 2025. PMID: 40107434 Review.
Advanced and recurrent endometrial cancer: State of the art and future perspectives.
Tronconi F, Nero C, Giudice E, Salutari V, Musacchio L, Ricci C, Carbone MV, Ghizzoni V, Perri MT, Camarda F, Gentile M, Berardi R, Scambia G, Lorusso D. Tronconi F, et al. Among authors: ghizzoni v. Crit Rev Oncol Hematol. 2022 Dec;180:103851. doi: 10.1016/j.critrevonc.2022.103851. Epub 2022 Oct 17. Crit Rev Oncol Hematol. 2022. PMID: 36257537 Review.
Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives.
Giudice E, Salutari V, Sassu CM, Ghizzoni V, Carbone MV, Vertechy L, Fagotti A, Scambia G, Marchetti C. Giudice E, et al. Among authors: ghizzoni v. Expert Rev Anticancer Ther. 2024 Aug;24(8):649-655. doi: 10.1080/14737140.2024.2362178. Epub 2024 Jun 11. Expert Rev Anticancer Ther. 2024. PMID: 38861580 Free article. Review.
26 results